Analyst Price Targets — NATI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 13, 2022 8:18 am | — | Morgan Stanley | $52.00 | $39.02 | Benzinga | Morgan Stanley Maintains Overweight on National Instruments, Raises Price Target to $52 |
| July 14, 2022 9:56 am | — | J.P. Morgan | $35.00 | $30.70 | Benzinga | JP Morgan Maintains Neutral on National Instruments, Lowers Price Target to $35 |
| June 20, 2022 8:19 am | Mark Delaney | Goldman Sachs | $43.00 | $31.44 | Pulse 2.0 | National Instruments (NATI) Stock: $43 Target And Buy Rating |
Latest News for NATI
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”),…
Vancouver B.C., June 10, 2026 (GLOBE NEWSWIRE) -- TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF , FSE: C 9O0) is pleased to announce that it has completed an independent National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) Technical Report (the “Technical Report”) for its wholly-owned Marysvale Uranium Mines Project located in the historic Marysvale…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NATI.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.